INRLF
Price
$2.82
Change
-$0.10 (-3.42%)
Updated
Apr 11 closing price
Capitalization
497.92M
IUGNF
Price
$0.02
Change
-$0.01 (-33.33%)
Updated
Apr 11 closing price
Capitalization
111.54M
Ad is loading...

INRLF vs IUGNF

Header iconINRLF vs IUGNF Comparison
Open Charts INRLF vs IUGNFBanner chart's image
Valneva SE
Price$2.82
Change-$0.10 (-3.42%)
Volume$600
Capitalization497.92M
Imugene
Price$0.02
Change-$0.01 (-33.33%)
Volume$110.59K
Capitalization111.54M
INRLF vs IUGNF Comparison Chart
Loading...
View a ticker or compare two or three
VS
INRLF vs. IUGNF commentary
Apr 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INRLF is a Hold and IUGNF is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 12, 2025
Stock price -- (INRLF: $2.82 vs. IUGNF: $0.02)
Brand notoriety: INRLF and IUGNF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INRLF: 95% vs. IUGNF: 89%
Market capitalization -- INRLF: $497.92M vs. IUGNF: $111.54M
INRLF [@Biotechnology] is valued at $497.92M. IUGNF’s [@Biotechnology] market capitalization is $111.54M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INRLF’s FA Score shows that 0 FA rating(s) are green whileIUGNF’s FA Score has 0 green FA rating(s).

  • INRLF’s FA Score: 0 green, 5 red.
  • IUGNF’s FA Score: 0 green, 5 red.
According to our system of comparison, both INRLF and IUGNF are a bad buy in the long-term.

Price Growth

INRLF (@Biotechnology) experienced а -3.42% price change this week, while IUGNF (@Biotechnology) price change was +8.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.15%. For the same industry, the average monthly price growth was -16.20%, and the average quarterly price growth was -17.21%.

Industries' Descriptions

@Biotechnology (+0.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
INRLF($498M) has a higher market cap than IUGNF($112M). INRLF YTD gains are higher at: 34.928 vs. IUGNF (-9.302). INRLF has higher annual earnings (EBITDA): 21.2M vs. IUGNF (-125.5M).
INRLFIUGNFINRLF / IUGNF
Capitalization498M112M445%
EBITDA21.2M-125.5M-17%
Gain YTD34.928-9.302-375%
P/E RatioN/AN/A-
Revenue159MN/A-
Total Cash156MN/A-
Total Debt201MN/A-
FUNDAMENTALS RATINGS
INRLF: Fundamental Ratings
INRLF
OUTLOOK RATING
1..100
92
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
PROFIT vs RISK RATING
1..100
97
SMR RATING
1..100
90
PRICE GROWTH RATING
1..100
46
P/E GROWTH RATING
1..100
68
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NABZY10.610.46
+4.53%
National Australia Bank Ltd. (Victoria, Australia)
FRFHF1437.9750.96
+3.67%
Fairfax Financial Holdings Ltd.
JRNGF0.970.02
+2.21%
Journey Energy Inc.
TYCMY34.120.08
+0.22%
Tingyi Cayman Islands Holdings Corp.
SRNW0.12N/A
-0.33%
Stratos Renewables Corp.

INRLF and

Correlation & Price change

A.I.dvisor indicates that over the last year, INRLF has been loosely correlated with VALN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if INRLF jumps, then VALN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INRLF
1D Price
Change %
INRLF100%
-3.42%
VALN - INRLF
42%
Loosely correlated
-0.32%
IKT - INRLF
22%
Poorly correlated
+11.29%
IMMX - INRLF
21%
Poorly correlated
+6.97%
NBTX - INRLF
20%
Poorly correlated
+4.86%
VXRT - INRLF
20%
Poorly correlated
+13.30%
More

IUGNF and

Correlation & Price change

A.I.dvisor tells us that IUGNF and DRUG have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IUGNF and DRUG's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IUGNF
1D Price
Change %
IUGNF100%
-22.00%
DRUG - IUGNF
21%
Poorly correlated
+0.24%
OTLC - IUGNF
13%
Poorly correlated
+3.31%
INRLF - IUGNF
8%
Poorly correlated
-3.42%
KNBIF - IUGNF
7%
Poorly correlated
N/A
INNMF - IUGNF
2%
Poorly correlated
N/A
More